Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome
Ist Teil von
Journal of cancer research and clinical oncology, 2008-02, Vol.134 (2), p.227-236
Ort / Verlag
Berlin/Heidelberg: Springer-Verlag
Erscheinungsjahr
2008
Quelle
MEDLINE
Beschreibungen/Notizen
Purpose
Variable uptake of
18
FDG has been noticed in positron emission tomography (PET) studies of patients with oesophageal adenocarcinoma. The aim of the present study was to investigate biological parameters involved in
18
FDG uptake in oesophageal adenocarcinoma for selection of patients with increased
18
FDG uptake and prediction of prognostic value of
18
FDG PET.
Patients and methods
Preoperative PET scans were performed in 26 patients with histologically proven oesophageal adenocarcinoma.
18
FDG uptake was semiquantitatively measured by SUV
BSAg.
Tumour sections were stained by immunohistochemistry for angiogenic markers (VEGF, CD31), glucose transporter-1 (Glut-1), hexokinase (HK) isoforms, for proliferation marker (Ki67), for macrophage marker (CD68) and for apoptosis marker (cleaved caspase-3). Cell densities, differentiation grade, degree of necrosis and mucus, T-stage and tumour size were assessed. In addition follow-up was analysed.
Results
No association was found between
18
FDG uptake and angiogenic markers. In contrast, a significant correlation was found between
18
FDG uptake and Glut-1 expression. No correlations were found between
18
FDG uptake and HK isoforms, Ki67 or cleaved caspase-3. Also, no correlations were found between
18
FDG uptake and cell density, differentiation grade, CD68, mucus and necrosis. However, there was a significant correlation between
18
FDG uptake and tumour size and between
18
FDG uptake and tumour recurrence.
Conclusions
Glut-1 expression and tumour size seem parameters associated with
18
FDG uptake in patients with biopsy proven oesophageal adenocarcinoma, and may be used to select oesophageal cancer patients in whom
18
FDG-PET is of diagnostic value and may predict disease outcome.